Screener
Corcept Therapeutics CORT Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Preferred stock | — | — |
| Common stock | 142 | 140 |
| Treasury stock | (998,013) | (966,586) |
| Additional paid-in capital | 1,048,598 | 968,600 |
| Accumulated other comprehensive income | 436 | 2,264 |
| Retained earnings | 654,613 | 643,387 |
| Total stockholders’ equity | 705,776 | 647,805 |
| Total liabilities and stockholders’ equity | $888,702 | $836,651 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's total equity?
- Corcept Therapeutics (CORT) reported total equity of $705.78M in Q2 2026.
- How has Corcept Therapeutics's total equity changed year-over-year?
- Corcept Therapeutics's total equity increased by 11.0% year-over-year, from $635.79M to $705.78M.
- What is the long-term trend for Corcept Therapeutics's total equity?
- Over 5 years (2020 to 2025), Corcept Therapeutics's total equity has grown at a 4.4% compound annual growth rate (CAGR), from $523.34M to $647.81M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Corcept Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude